%0 Journal Article
%A Nishio, Makoto
%A Barlesi, Fabrice
%A West, Howard
%A Ball, Simon
%A Bordoni, Rodolfo
%A Cobo, Manuel
%A Longeras, Pascale Dubray
%A Goldschmidt, Jerome
%A Novello, Silvia
%A Orlandi, Francisco
%A Sanborn, Rachel E
%A Szalai, Zsuzsanna
%A Ursol, Grigoriy
%A Mendus, Diana
%A Wang, Lijia
%A Wen, Xiaohui
%A McCleland, Mark
%A Hoang, Tien
%A Phan, See
%A Socinski, Mark A
%T Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial.
%D 2020
%U http://hdl.handle.net/10668/16813
%X We report the final results of the phase 3 IMpower132 study evaluating atezolizumab plus carboplatin or cisplatin plus pemetrexed (APP) in patients with nonsquamous NSCLC. Chemotherapy-naive patients with stage IV nonsquamous NSCLC without sensitizing EGFR or ALK genetic alterations were randomized in a one-to-one ratio to receive four or six cycles of carboplatin or cisplatin plus pemetrexed (PP) or APP every 3 weeks, followed by maintenance therapy with atezolizumab plus pemetrexed or pemetrexed alone. Co-primary end points were overall survival (OS) and investigator-assessed progression-free survival (PFS). The intention-to-treat population included 578 patients (APP, n = 292; PP, n = 286). At the primary PFS analysis (May 22, 2018; median follow-up, 14.8 mo), APP exhibited significant PFS improvement versus PP (median = 7.6 versus 5.2 mo, stratified hazard ratio [HR] = 0.60, 95% confidence interval [CI]: 0.49-0.72, p  IMpower132 met its co-primary PFS end point but not its co-primary OS end point, with numerical improvement for OS in the APP arm. APP had a manageable safety profile, with no new or unexpected safety signals identified.
%K Atezolizumab
%K Lung cancer
%K Nonsquamous
%K Non–small cell
%~